Literature DB >> 24900107

Myocardial Fibrosis in Hypertrophic Cardiomyopathy Demonstrated by Integrated Cardiac F-18 FDG PET/MR.

Eun-Jung Kong1, Sang-Hee Lee2, Ihn-Ho Cho1.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a common condition defined as a diffuse or segmental left ventricular (LV) hypertrophy with a nondilated and hyperdynamic chamber as well as cardiac arrhythmias. Cardiac MR (CMR) imaging is a key modality for evaluation of HCM. In addition to the assessment of LV wall thickness, LV function and aortic flow, CMR is capable of estimation of late gadolinium enhancement (LGE) in affected myocardium which has been shown to have a direct correlation with incidence and severity of arrhythmias in HCM. In patients with HCM, LGE on CMR is presumed to represent intramyocardial fibrosis. Meanwhile, F-18 FDG myocardial PET has been sporadically studied in HCM, mostly for evaluation of the metabolic status of a hypertrophic myocardial segment, especially after interventions or to demonstrate partial myocardial fibrosis. We presented here the case of a 25-year-old male patient referred for simultaneous F-18 FDG cardiac PET/MR for the evaluation of septal hypertrophy. The PET/MR revealed myocardial fibrosis in the septum associated with FDG-defect and LGE.

Entities:  

Keywords:  Cardiovascular magnetic resonance; FDG; Fibrosis; Hypertrophic cardiomyopathy; PET/MRI

Year:  2013        PMID: 24900107      PMCID: PMC4035195          DOI: 10.1007/s13139-013-0201-0

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  17 in total

1.  Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy.

Authors:  T Kuribayashi; W C Roberts
Journal:  Am J Cardiol       Date:  1992-11-15       Impact factor: 2.778

2.  PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy.

Authors:  Paco E Bravo; Aurélio Pinheiro; Takahiro Higuchi; Christoph Rischpler; Jennifer Merrill; Miguel Santaularia-Tomas; M Roselle Abraham; Richard L Wahl; Theodore P Abraham; Frank M Bengel
Journal:  J Nucl Med       Date:  2012-02-07       Impact factor: 10.057

3.  Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal:  Circ Heart Fail       Date:  2008-06-23       Impact factor: 8.790

4.  Comparison of (99m)Tc-MIBI SPECT/18F-FDG PET imaging and cardiac magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy: assessment of cardiac function and myocardial injury.

Authors:  Lei Wang; Chaowu Yan; Shihua Zhao; Wei Fang
Journal:  Clin Nucl Med       Date:  2012-12       Impact factor: 7.794

Review 5.  Hypertrophic cardiomyopathy: a systematic review.

Authors:  Barry J Maron
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

6.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.

Authors:  A Selcuk Adabag; Barry J Maron; Evan Appelbaum; Caitlin J Harrigan; Jacqueline L Buros; C Michael Gibson; John R Lesser; Constance A Hanna; James E Udelson; Warren J Manning; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

7.  Quantitative FDG-uptake by positron emission tomography in progressive hypertrophy of rat hearts in vivo.

Authors:  Nobuhiro Handa; Yasuhiro Magata; Takahiro Mukai; Takeshi Nishina; Junji Konishi; Masashi Komeda
Journal:  Ann Nucl Med       Date:  2007-12-25       Impact factor: 2.668

8.  Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.

Authors:  Ronen Rubinshtein; James F Glockner; Steve R Ommen; Philip A Araoz; Michael J Ackerman; Paul Sorajja; J Martijn Bos; A Jamil Tajik; Uma S Valeti; Rick A Nishimura; Bernard J Gersh
Journal:  Circ Heart Fail       Date:  2009-10-22       Impact factor: 8.790

9.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  Barry J Maron; Paolo Spirito; Win-Kuang Shen; Tammy S Haas; Francesco Formisano; Mark S Link; Andrew E Epstein; Adrian K Almquist; James P Daubert; Thorsten Lawrenz; Giuseppe Boriani; N A Mark Estes; Stefano Favale; Marco Piccininno; Stephen L Winters; Massimo Santini; Sandro Betocchi; Fernando Arribas; Mark V Sherrid; Gianfranco Buja; Christopher Semsarian; Paolo Bruzzi
Journal:  JAMA       Date:  2007-07-25       Impact factor: 56.272

Review 10.  Imaging techniques in the evaluation and management of hypertrophic cardiomyopathy.

Authors:  Alyson Kelley-Hedgepeth; Martin S Maron
Journal:  Curr Heart Fail Rep       Date:  2009-09
View more
  8 in total

Review 1.  Cardiac Applications of PET-MR.

Authors:  Peter J Bergquist; Michael S Chung; Anja Jones; Mark A Ahlman; Charles S White; Jean Jeudy
Journal:  Curr Cardiol Rep       Date:  2017-05       Impact factor: 2.931

Review 2.  Disease-specific cardiovascular positron emission tomography/magnetic resonance imaging: a brief review of the current literature.

Authors:  Jeffrey M C Lau; Jie Zheng
Journal:  Quant Imaging Med Surg       Date:  2016-06

Review 3.  Positron emission tomography/MRI for cardiac diseases assessment.

Authors:  Osamu Manabe; Noriko Oyama-Manabe; Nagara Tamaki
Journal:  Br J Radiol       Date:  2020-02-14       Impact factor: 3.039

4.  Prognostic Value of Normal Perfusion but Impaired Left Ventricular Function in the Diabetic Heart on Quantitative Gated Myocardial Perfusion SPECT.

Authors:  Hwan-Jeong Jeong; Dong Soo Lee; Ho-Young Lee; SeHun Choi; Yeon-Hee Han; June-Key Chung
Journal:  Nucl Med Mol Imaging       Date:  2013-07-20

Review 5.  Gating Approaches in Cardiac PET Imaging.

Authors:  Martin Lyngby Lassen; Jacek Kwiecinski; Piotr J Slomka
Journal:  PET Clin       Date:  2019-02-01

6.  A two-stage cardiac PET and late gadolinium enhancement MRI co-registration method for improved assessment of non-ischemic cardiomyopathies using integrated PET/MR.

Authors:  Zheng Zhang; Xing Chen; Qing Wan; Haiyan Wang; Na Qi; Zhiwen You; Jianmin Yuan; Lingzhi Hu; Hongwei Sun; Zhe Wang; Chenxi Hu; Jun Zhao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-15       Impact factor: 10.057

7.  Monitoring of Cardiac Remodeling in a Mouse Model of Pressure-Overload Left Ventricular Hypertrophy with [18F]FDG MicroPET.

Authors:  Andrei Todica; Nick L Beetz; Lisa Günther; Mathias J Zacherl; Ulrich Grabmaier; Bruno Huber; Peter Bartenstein; Stefan Brunner; Sebastian Lehner
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

8.  Radiopharmaceutical tracers for cardiac imaging.

Authors:  Osamu Manabe; Tatsuya Kikuchi; Arthur J H A Scholte; Mohammed El Mahdiui; Ryuichi Nishii; Ming-Rong Zhang; Eriko Suzuki; Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2017-12-01       Impact factor: 5.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.